HYEX — what changed in the latest 10-Q
A section-by-section comparison of HYEX's newest periodic SEC filing (10-K/10-Q) against the prior same-form filing: paragraphs added and removed per section, with verbatim excerpts. Purely a deterministic text diff — no similarity scores, no directional read, not investment advice.
Comparing 10-Q · 2026-05-14 vs the prior 10-Q · 2025-11-14
| Section | Outcome | Added | Removed | Minor | Unchanged |
|---|---|---|---|---|---|
| MD&A | Text added/removed | +12 | −12 | ~11 | 23 |
| Market risk (Item 3) | Text added/removed | +2 | −2 | ~3 | 17 |
| Controls & procedures | Text added/removed | +2 | −2 | ~3 | 16 |
| Legal proceedings | Text added/removed | +2 | −2 | ~1 | 15 |
| Risk factors | Text added/removed | +2 | −2 | ~1 | 13 |
| Other information | Text added/removed | 0 | −1 | ~1 | 10 |
Counts are paragraphs; added/removed means text added or removed vs the prior filing — no direction or judgement implied.
Representative excerpts
Up to 5 excerpts of about 300 characters per section, quoted verbatim from the two SEC filings.
MD&A
Text added vs the prior filing · source: 10-Q · 2026-05-14
Guided by this mission, our first two acquisitions (in 2019 and 2020, respectively) formed our historical operating subsidiaries, BergaMet NA, LLC, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health. Our GummyUSA acquisition (in…
We had revenues of $1,610,744 for the three months ended March 31, 2026, compared to $931,280 for the three months ended March 31, 2025, an increase of $679,464, or 73%. We expect revenue growth to increase as our direct consumer sales and marketing efforts continue to perform.
Cost of revenue as a percentage of revenues was 39% for the three months ended March 31, 2026, compared to 54% for the three months ended March 31, 2025.
Our general and administrative expenses were $1,317,403 for the three months ended March 31, 2026, compared to $533,833 for the three months ended March 31, 2025, an increase of $783,570, or 147%. In the three months ended March 31, 2026, general and administrative expenses consisted mainly of adver…
Other income (expense) was $128,112 for the three months ended March 31, 2026, compared to $(290,011) for the three months ended March 31, 2025, an increase of $418,123, or 144%. In the three months ended March 31, 2026, other income (expense) consisted of interest expense, net of interest income of…
Text removed vs the prior filing · source: 10-Q · 2025-11-14
Guided by this mission, our first two acquisitions formed our current operating subsidiaries, BergaMet NA, LLC, which offers nutraceutical heart and immune health products, and UBN, which offers nutraceutical products for brain health. Based on published research from third-party sources, we believe…
We had revenues of $917,975 and $2,817,910 for the three and nine months ended September 30, 2025, compared to $744,916 and $2,342,091 for the three and nine months ended September 30, 2024, an increase of $173,058, or 23%, and $475,819, or 20%, respectively. We expect strong growth to increase as o…
Cost of revenue as a percentage of revenues was 51% and 48% for the three and nine months ended September 30, 2025, compared to 19% and 36% for the three and nine months ended September 30, 2024. The reduced cost as a percentage of revenues in the three months ended September 30, 2025 was due to eff…
Our general and administrative expenses were $907,363 and $2,139,630 for the three and nine months ended September 30, 2025, compared to $517,068 and $1,485,945 for the three and nine months ended September 30, 2024, an increase of $390,295, or 75%, and $653,685, or 44%, respectively. In the three m…
Other income (expense) was $64,720 and $(52,565) for the three and nine months ended September 30, 2025, compared to $269,074 and $(404,703) for the three and nine months ended September 30, 2024, a decrease of $204,354, or 76%, and $352,138, or 87%, respectively. In the three months ended September…
Market risk (Item 3)
Text added vs the prior filing · source: 10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
Text removed vs the prior filing · source: 10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
Controls & procedures
Text added vs the prior filing · source: 10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
Text removed vs the prior filing · source: 10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
Legal proceedings
Text added vs the prior filing · source: 10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
Text removed vs the prior filing · source: 10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
Risk factors
Text added vs the prior filing · source: 10-Q · 2026-05-14
On March 20, 2026, we issued 20,000 shares of our common stock, restricted in accordance with Rule 144, to two shareholders for services rendered. The issuances were exempt from registration pursuant to Section 4(a)(1) of the Securities Act of 1933, and the shareholders were accredited.
There have been no other events which are required to be reported under this Item.
Text removed vs the prior filing · source: 10-Q · 2025-11-14
There have been no events which are required to be reported under this Item.
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
Other information
Text removed vs the prior filing · source: 10-Q · 2025-11-14
Incorporated by reference from our Annual Report on Form 10-K filed with the Commission on August 3, 2021.
How to read Risk Factors (Item 1A) in a 10-Q
A 10-Q risk-factor section usually takes one of three forms; this page classifies it as one of:
- Pointer — the filer states there have been no material changes and points back to the annual 10-K risk factors; there is no own risk text to compare this quarter.
- Partial update — the filer carves out specific updated risks ("except as set forth below"); the excerpts show exactly what is new this quarter.
- Restated in full — the quarter carries the complete risk-factor text. When the prior quarter was only a pointer there is no prior full text to diff against, so the page flags the section as restated instead.
This describes the filing structure only — it is never a judgement on whether risk went up or down.
Source: text-level diff of the two SEC EDGAR filings · deterministic (no AI-generated content) · for reference only · not investment advice